ICCC
ImmuCell Corporation
NASDAQ · Healthcare · Biotechnology · US
$9.90
−1.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 30.7M | 27.6M | 26.5M | 17.5M | 18.6M |
| Cost of Revenue | 18.3M | 16.2M | 18.6M | 13.1M | 10.9M |
| Gross Profit | 12.4M | 11.4M | 7.9M | 4.4M | 7.6M |
| Operating Expenses | |||||
| R&D Expense | 1.9M | 3.0M | 3.9M | 4.4M | 4.5M |
| SG&A Expense | 8.6M | 6.8M | 5.7M | 5.2M | 5.5M |
| General & Admin Expense | 4.3M | 3.2M | 2.2M | 2.1M | 2.3M |
| Selling & Marketing Expense | 4.3M | 3.6M | 3.5M | 3.1M | 3.2M |
| Other Expenses | (2.0M) | — | — | 527.0K | — |
| Total Operating Expenses | 8.5M | 9.8M | 9.6M | 10.1M | 9.9M |
| Cost and Expenses | 26.8M | 26.0M | 28.1M | 23.2M | 20.9M |
| Operating Income (EBIT) | 3.9M | 1.6M | (1.6M) | (5.7M) | (2.3M) |
| Non-Operating | |||||
| Interest Income | 182.8K | 158.7K | 77.7K | 96.6K | 153.1K |
| Interest Expense | 432.8K | 439.0K | 568.7K | 453.0K | 348.5K |
| Net Interest Income | (250.0K) | (280.3K) | (491.0K) | (356.4K) | (195.4K) |
| Other Non-Op Income/Expense | (3.0M) | (2.7M) | (506.4K) | (21.9K) | (186.8K) |
| Non-Operating Income (excl Interest) | 2.7M | 2.2M | (19.6K) | (527.0K) | (161.3K) |
| EBT (Pre-Tax Income) | 853.6K | (1.0M) | (2.1M) | (5.8M) | (2.5M) |
| Income Tax Expense | 66.2K | 11.6K | 10.1K | 4.6K | 8.0K |
| Bottom Line | |||||
| Net Income | 787.4K | (1.0M) | (2.2M) | (5.8M) | (2.5M) |
| Earnings from Cont. Ops | 787.4K | (1.0M) | (2.2M) | (5.8M) | (2.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 787.4K | (1.0M) | (2.2M) | (5.8M) | (2.5M) |
| Per Share | |||||
| Basic EPS | $0.08 | ($0.12) | ($0.26) | ($0.75) | ($0.32) |
| Diluted EPS | $0.08 | ($0.12) | ($0.26) | ($0.75) | ($0.32) |
| Revenue Per Share | $3.38 | $3.06 | $3.24 | $2.27 | $2.40 |
| Shares | |||||
| Basic Shares Outstanding | 9.1M | 9.0M | 8.2M | 7.7M | 7.7M |
| Diluted Shares Outstanding | 9.2M | 9.0M | 8.2M | 7.7M | 7.7M |
| Profitability Metrics | |||||
| EBITDA | 3.5M | 2.1M | 1.1M | (2.5M) | 350.0K |
| D&A | 2.4M | 2.7M | 2.7M | 2.7M | 2.5M |
| EBIT | 1.2M | (589.4K) | (1.6M) | (5.2M) | (2.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026